Altimmune to Participate at Two Upcoming Investor Conferences
H.C. Wainwright7th Annual NASH Investor Conference( Virtual Conference) Tuesday, October 24, 2023
10:00 am Eastern Time H. C. Wainwright4th Annual Hepatitis B Virus (HBV) Virtual Conference Wednesday, October 25, 2023
Fireside chat at
3:00 pm Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Altimmune Investor Contact:
Chief Financial Officer
Source: Altimmune, Inc